JP2024514098A - ＥｒｂＢ２突然変異体を標的とする阻害薬の調製における化合物の使用 - Google Patents

ＥｒｂＢ２突然変異体を標的とする阻害薬の調製における化合物の使用 Download PDF

Info

Publication number
JP2024514098A
JP2024514098A JP2023560644A JP2023560644A JP2024514098A JP 2024514098 A JP2024514098 A JP 2024514098A JP 2023560644 A JP2023560644 A JP 2023560644A JP 2023560644 A JP2023560644 A JP 2023560644A JP 2024514098 A JP2024514098 A JP 2024514098A
Authority
JP
Japan
Prior art keywords
structure represented
erbb2
cancer
formula
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023560644A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024514098A5 (https=
JPWO2022206929A5 (https=
Inventor
ディ リ
リンジュン ドゥアン
ユアン ホン
ジーフー ツァン
グォンシン シヤ
イン クー
Original Assignee
シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド filed Critical シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド
Publication of JP2024514098A publication Critical patent/JP2024514098A/ja
Publication of JP2024514098A5 publication Critical patent/JP2024514098A5/ja
Publication of JPWO2022206929A5 publication Critical patent/JPWO2022206929A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023560644A 2021-04-01 2022-03-31 ＥｒｂＢ２突然変異体を標的とする阻害薬の調製における化合物の使用 Pending JP2024514098A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110358192 2021-04-01
CN202110358192.3 2021-04-01
PCT/CN2022/084650 WO2022206929A1 (zh) 2021-04-01 2022-03-31 一种化合物在制备靶向ErbB2突变体的抑制药物中的应用

Publications (3)

Publication Number Publication Date
JP2024514098A true JP2024514098A (ja) 2024-03-28
JP2024514098A5 JP2024514098A5 (https=) 2024-04-11
JPWO2022206929A5 JPWO2022206929A5 (https=) 2024-04-11

Family

ID=83458071

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023560644A Pending JP2024514098A (ja) 2021-04-01 2022-03-31 ＥｒｂＢ２突然変異体を標的とする阻害薬の調製における化合物の使用

Country Status (5)

Country Link
US (1) US20240197737A1 (https=)
EP (1) EP4316491A4 (https=)
JP (1) JP2024514098A (https=)
CN (1) CN115192580A (https=)
WO (1) WO2022206929A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4323356A1 (en) 2021-04-13 2024-02-21 Nuvalent, Inc. Amino-substituted heterocycles for treating cancers with egfr mutations
CN116606289B (zh) * 2022-02-17 2026-02-24 上海医药集团股份有限公司 一种含氮杂环化合物的晶型、制备方法及应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007095038A2 (en) * 2006-02-09 2007-08-23 Novartis Ag Mutations and polymorphisms of erbb2
EP3424928A1 (en) * 2016-03-01 2019-01-09 Shanghai Pharmaceuticals Holding Co., Ltd. Nitrogenous heterocyclic compound, preparation method, intermediate, composition and use
EP3677583A1 (en) * 2017-09-01 2020-07-08 Shanghai Pharmaceuticals Holding Co., Ltd. Nitrogenous heterocyclic compound, preparation method, intermediate, composition, and application
WO2020205521A1 (en) * 2019-03-29 2020-10-08 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 insertions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007095038A2 (en) * 2006-02-09 2007-08-23 Novartis Ag Mutations and polymorphisms of erbb2
EP3424928A1 (en) * 2016-03-01 2019-01-09 Shanghai Pharmaceuticals Holding Co., Ltd. Nitrogenous heterocyclic compound, preparation method, intermediate, composition and use
EP3677583A1 (en) * 2017-09-01 2020-07-08 Shanghai Pharmaceuticals Holding Co., Ltd. Nitrogenous heterocyclic compound, preparation method, intermediate, composition, and application
WO2020205521A1 (en) * 2019-03-29 2020-10-08 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 insertions

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CANCER RESEARCH, vol. 66, no. 13, JPN6026013216, 2006, pages 6487 - 6491, ISSN: 0005834558 *
CLINICAL CANCER RESEARCH, vol. 24, no. 20, JPN6026013215, 2018, pages 5112 - 5122, ISSN: 0005834557 *
ONCOGENE, vol. 26, JPN6026013218, 2007, pages 5023 - 5027, ISSN: 0005834560 *
THORACIC CANCER, vol. 11, JPN6026013217, 2020, pages 2051 - 2055, ISSN: 0005834559 *

Also Published As

Publication number Publication date
EP4316491A4 (en) 2025-05-07
WO2022206929A1 (zh) 2022-10-06
EP4316491A1 (en) 2024-02-07
US20240197737A1 (en) 2024-06-20
CN115192580A (zh) 2022-10-18

Similar Documents

Publication Publication Date Title
US11291667B2 (en) Combination therapy involving diaryl macrocyclic compounds
JP7530390B2 (ja) 新規ｅｇｆｒ阻害剤
CN115607551A (zh) Egfr抑制剂的新用途
TW202136252A (zh) 化合物及其用途
AU2015101598A4 (en) Novel ros1 inhibitor and its use
WO2023045816A1 (zh) 作为axl抑制剂的苯并环庚烷类化合物
JP2019511554A (ja) 静止細胞標的化およびｅｇｆｒ阻害剤を用いた新生物の処置のための組み合わせ
JP2023540491A (ja) 突然変異型ｅｇｆｒ阻害化合物およびその適用
EP4171556A1 (en) A combination of a cbp/p300 bromodomain inhibitor and an egfr inhibitor for use in treating egfr-mutant nsclc
US20140350050A1 (en) Pyridine compounds as inhibitors of kinase
JP2024514098A (ja) ＥｒｂＢ２突然変異体を標的とする阻害薬の調製における化合物の使用
WO2017129094A1 (zh) 一种egfr/her2受体酪氨酸激酶抑制剂在制备治疗her2突变癌症药物中的用途
CN119031916A (zh) 包含sos1抑制剂和egfr抑制剂的组合疗法
CN108078990B (zh) 喹唑啉衍生物类酪氨酸激酶抑制剂的新用途
CN115785107B (zh) 一种取代8,9-二氢嘧啶并[5,4-b]吲嗪类化合物、药物组合物及其用途
JP2025511161A (ja) Ｋｒａｓ ｇ１２ｃ阻害剤及びｔｅａｄ阻害剤の治療的組合せ
CN110840892A (zh) 酪氨酸激酶抑制剂与cdk4/6抑制剂联合在制备预防或治疗肿瘤疾病的药物中的用途
TW201625254A (zh) 以吡羧醯胺化合物作為有效成分之醫藥組成物
JPWO2019195753A5 (https=)
EP4698176A1 (en) Treatment of cancer with a met kinase inhibitor
HK40105285A (en) Application of compound in preparation of inhibitory drug targeting erbb2 mutant
CN115721649A (zh) 抑制突变型egfr的化合物及其应用
CN112194652B (zh) 4-羟甲基-1h-吲哚类化合物、制备方法及应用
CN115721650A (zh) 抑制突变型egfr的化合物及其应用
WO2025085652A1 (en) Indole carboxamides useful as rac1 inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240329

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260407